Search
Menu
Home
HTB
2004
May
May 2004
Contents
Editorial
Volume 5 Number 4 May 2004
Conference reports
5th International Workshop on Clinical Pharmacology of HIV Therapy, 1-3 April 2004, Rome, Italy
Large reductions in plasma PK levels of saquinavir, amprenavir and lopinavir/r levels when given with tipranavir/ritonavir
Good generic drugs and good adherence in Rwanda
Steady state PK of nelfinavir and M8 in pregnancy
Higher nelfinavir concentrations improve response in children
PK of once daily lopinavir/r in children
2nd European HIV Drug Resistance Workshop, 11-13 March 2004, Rome, Italy
Understanding developments in HIV drug resistance for new drugs and targets — atazanavir, fusion (T-20) and receptor inhibitors
11th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2004, San Francisco
HIV-associated dementia and cognitive dysfunction
Diabetes and HIV and HCV; aging/HIV and diabetes
Antiretrovirals
US treatment guidelines updated – March 2004
Atazanavir launched in UK
Tenofovir/FTC co-formulation application made to EMEA
Abacavir/3TC co-formulation available in expanded access
Treatment access
Outcomes after two years of providing antiretrovirals in Khayelitsha, South Africa
A round-up of news on access to treatments
Pregnancy
Post partum complications in HIV-positive women
Paediatric care
Children’s HIV National Network (CHINN) Review
FDA approves new paediatric dose of nelfinavir
PK and drug interactions
Eating grapefruit triggers statin-related rhabdomyolysis
Side effects
FDA panel recommends approval of New-fill
Lipodystrophy regresses in three patients switched to atazanavir
Cancer and HIV
Surgery and HAART are an effective combination for treating HPV-associated lesions
Other news
Postexposure prophylaxis does not lead to an increase in high-risk behaviour
Law would permit HIV-positive organ donation
A guide to applying to the Global Fund is released
On the web
Conference reports
Online medical training
Newletters and journals
PDFs
Volume 5 Number 4 May 2004 PDF
HTB RSS
Early access
Long-acting injectable PrEP approved in the US: priced at $28,000 a year
28 June 2025
Clinical studies of two once-weekly pipeline compounds put on hold
27 June 2025
UK HIV care for transgender and non-binary people: comment on unworkable EHRC guidelines by 30 June
26 June 2025
UK guidelines on doxyPEP to prevent syphilis
17 June 2025
All early access reports
Current issues
June 2025
May 2025
April 2025
Back issues
Special report
UK HIV care for transgender and non-binary people: comment on unworkable EHRC guidelines by 30 June
26 June 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate